Loading clinical trials...
Loading clinical trials...
The REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study is the largest prospective multicenter data base for CIN flowing coronary angiography (CAG) or percutaneous coronary intervention ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Guangdong Provincial People's Hospital
Collaborators
NCT04982419 · Acute Kidney Injury, Heart Failure, and more
NCT02516072 · Remote Ischaemic Preconditioning, Contrast Induced Nephropathy
NCT01999517 · Contrast Induced Nephropathy
NCT02106234 · Contrast Induced Nephropathy, Acute Kidney Injury
NCT03121053 · Aortic Valve Disease, Chronic Kidney Disease, and more
Kaihong Chen
Longyan, Fujian
Guoliang Jia
Dongguan, Guangdong
Jianfeng Ye
Dongguan, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions